Primary tabs

ACT-709478

New Drugs in Development
  • PRE
  • P1
  • P2
  • P3
Sponsors / Collaborators Actelion (J&J company) / Idorsia Pharmaceuticals Ltd.
Mechanism of Action Ion Channel
: Selective T-type Calcium Channel Blocker
Populations Tested In Photosensitive epilepsy
Special FDA Designation
  • N/A
Nonprofit / Government Support N/A
: N/A
Presented at meetings (latest date) (Pipeline, AEDD; AES, Eilat, etc) N/A
Location of Clinical Trials France / Germany

Our Mission

The mission of the Epilepsy Foundation is to lead the fight to overcome the challenges of living with epilepsy and to accelerate therapies to stop seizures, find cures, and save lives.

 
24/7 helpline
P